European label update of Bayer’s Xarelto now including guidance for use in AF patients undergoing cardioversion
This label update provides physicians with important information on the clinical utility of rivaroxaban in patients with AF who require cardioversion and is based on the positive CHMP
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.